Telix Pharmaceuticals Logo
Telix Pharmaceuticals Logo
  • Our Company
    • Our Company
    • Purpose, Mission & Values
    • Board & Management
    • Our Technology
    • Sustainability
  • Our Portfolio
    • Our Portfolio
    • Disease Areas
      • Prostate Cancer
      • Kidney Cancer
      • Brain Cancer
      • Musculo-skeletal cancers
    • Clinical Trials
    • Illuccix® & Gozellix®
    • Pipeline
    • Research & Innovation
  • Investor Centre
  • News & Views
  • Careers
    • Careers
    • Find a job
Header Image Frame Header Image Frame

Home News Page 38

News & Views

Latest News

Category: News

See all

First Patients Dosed in Clinical Trial of Novel Lung and Ovarian Cancer Theranostic

Clinical, News,

Telix announces first two patients dosed in phase I trial of lung & ovarian cancer...

Read more

Telix Pharmaceuticals Enters Strategic Collaboration with Varian Medical Systems for Advanced Prostate Imaging

ASX, News,

Telix announces it has entered into a strategic collaboration agreement with Varian Medical...

Read more

Telix Pharmaceuticals and IRE Elit Enter Distribution Partnership for Prostate Cancer Imaging

ASX, News,

Telix announces distribution agreement with Fleurus-based IRE Elit S.A. to distribute Telix’s prostate cancer imaging...

Read more

FDA Grants Orphan Drug Designation for TLX102

ASX, News,

Telix announces the FDA has granted ODD for 4-[211At] astato-l-phenylalanine for the treatment of multiple...

Read more

First Patient Dosed in Renal Cancer Imaging Study in Japan

Clinical, News,

Telix announces the first patient has been dosed in a Phase I/II study of Telix’s renal cancer diagnostic imaging product TLX250-CDx in...

Read more

Telix H1 2020 Results and Company Update Conference Call

ASX, News,

Telix will hold an investor conference call to present the Company’s H1 2020 financial results together with an update on Telix’s...

Read more

Drug Master File for Glioblastoma Therapy Product Filed with FDA

ASX, News,

Telix announces it has submitted a Drug Master File to the FDA for TLX101 (4-[131I]Iodol-phenylalanine...

Read more

Activities Report and Sales Note to Accompany Appendix 4C

ASX, News,

Telix Pharmaceuticals provides its Activities Report and Appendix 4C for the quarter ending 30th June 2020 and a Q2 2020 sales...

Read more

Telix Pharmaceuticals Receives $11.4M R&D Tax Refund

ASX, News,

Read more

Telix Pharmaceuticals and RefleXion Medical Enter Strategic Collaboration for Treatment of High-Risk Cancers

ASX, News,

Telix Pharmaceuticals Limited announces it has entered into a strategic collaboration agreement with RefleXion...

Read more

Posts pagination

1 … 37 38 39 … 45

Subscribe

* indicates required

By subscribing, you are agreeing to the terms of our Global Privacy Policy and provide consent to receive updates from Telix”

Telix Pharmaceuticals Logo
  • Our Company
  • Contact
  • Our Portfolio
  • Careers
  • Investor Centre
  • News & Views

© Telix Pharmaceuticals Limited. 55 Flemington Road, North Melbourne, VIC 3051, Australia.

The Telix Pharmaceuticals and the Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved.
This website is intended for corporate communication purposes only and is not intended as promotion or advertising to any audience in any country worldwide.

Privacy Policy. Terms of Use. Cookies Policy. Privacy Settings